Journal of Clinical Oncology, Vol 12, 1886-1889, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma

CJ Watling, DH Lee, DR Macdonald and JG Cairncross
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.

PURPOSE: We studied corticosteroid-induced magnetic resonance (MR) scan changes in patients with recurrent malignant glioma to determine if corticosteroid therapy started concurrently with investigational treatment might yield false-positive responses. PATIENTS AND METHODS: Ten symptomatic patients not on corticosteroids when malignant glioma recurred had a baseline MR scan performed before corticosteroid treatment, followed by serial scans at weekly intervals for 1 month while on dexamethasone (16 mg/d). The maximum cross-sectional areas and volumes of the gadolinium-enhancing regions (tumor) and T2-weighted abnormalities (tumor plus edema) were compared quantitatively and qualitatively for each series of scans. RESULTS: Nine of 10 patients (90%) had a measurable reduction in the size of the gadolinium- enhancing region or T2-weighted abnormality with corticosteroid treatment. The maximum cross-sectional area and volume of the gadolinium-enhancing region decreased by at least 25% in three of 10 patients (30%). The maximum cross-sectional area and volume of the T2- weighted abnormality decreased by at least 25% in five of 10 patients (50%). Maximum measurable radiologic improvement was evident within 2 weeks in most patients. MR scans were judged improved by the reporting neuroradiologist in seven of 10 (70%). These subjective visual improvements were also evident within 2 weeks, but generally described as slight or modest. CONCLUSION: Corticosteroid-induced MR scan reductions in tumor size may confound the assessment of response of recurrent malignant gliomas to investigational agents. For patients who start corticosteroids for symptom control, investigational treatment should be delayed until a new baseline MR image is established 2 weeks later. Response is then judged by comparing subsequent MR scans with the new corticosteroid-influenced baseline image.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908. [Full Text] [PDF]

				S. A. Grossman, K. A. Carson, S. Phuphanich, T. Batchelor, D. Peereboom, L. B. Nabors, G. Lesser, F. Hausheer, J. G. Supko, and for the New Approaches to Brain Tumor Therapy CNS Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas Neuro-oncol, August 1, 2008; 10(4): 608 - 616. [Abstract] [Full Text] [PDF]

				K. A. Bradley, I. F. Pollack, J. M. Reid, P. C. Adamson, M. M. Ames, G. Vezina, S. Blaney, P. Ivy, T. Zhou, M. Krailo, et al. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: A Children's Oncology Group phase I study Neuro-oncol, January 1, 2008; 10(5): 752 - 758. [Abstract] [Full Text] [PDF]

				W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]

				S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride Clin. Cancer Res., September 1, 2006; 12(17): 5174 - 5181. [Abstract] [Full Text] [PDF]

				J. E.C. Bromberg, M. D. Siemers, and M. J.B. Taphoorn Is a "vanishing tumor" always a lymphoma? Neurology, September 10, 2002; 59(5): 762 - 764. [Abstract] [Full Text] [PDF]

				Y. Ino, R. A. Betensky, M. C. Zlatescu, H. Sasaki, D. R. Macdonald, A. O. Stemmer-Rachamimov, D. A. Ramsay, J. G. Cairncross, and D. N. Louis Molecular Subtypes of Anaplastic Oligodendroglioma: Implications for Patient Management at Diagnosis Clin. Cancer Res., April 1, 2001; 7(4): 839 - 845. [Abstract] [Full Text]

				T. L. Chenevert, L. D. Stegman, J. M. G. Taylor, P. L. Robertson, H. S. Greenberg, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain Tumors J Natl Cancer Inst, December 20, 2000; 92(24): 2029 - 2036. [Abstract] [Full Text] [PDF]

				H. S. Friedman, W. P. Petros, A. H. Friedman, L. J. Schaaf, T. Kerby, J. Lawyer, M. Parry, P. J. Houghton, S. Lovell, K. Rasheed, et al. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., May 1, 1999; 17(5): 1516 - 1516. [Abstract] [Full Text] [PDF]